EC Number |
Substrates |
Organism |
Products |
Reversibility |
---|
1.14.14.B9 | (4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoate + [reduced NADPH-hemoprotein reductase] + O2 |
- |
Homo sapiens |
(4Z,7Z,10Z,13Z,16Z)-20-hydroxydocosa-4,7,10,13,16-pentaenoate + [oxidized NADPH-hemoprotein reductase] + H2O |
main product, plus minor amounts of 21-hydroxy-4,7,10,13,16-(Z)-docosapentaenoic acid, no significant formation of dihydroxycompounds |
? |
1.14.14.B9 | (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate + [reduced NADPH-hemoprotein reductase] + O2 |
- |
Homo sapiens |
(4Z,7Z,10Z,13Z,16Z)-19,20-epoxydocosa-4,7,10,13,16-pentaenoate + [oxidized NADPH-hemoprotein reductase] + H2O |
formation of 19,20-epoxydocosapentaenoic acid, 16,17-epoxydocosahexaenoic acid, 13,14-epoxydocosahexaenoic acid, and 10,11-epoxydocosahexaenoic acid, no significant formation of 21-hydroxy- or 22-hydroxydocosahexaenoic acid. Reaction is catalyzed by both isoforms CYP4F8 and CYP4F12 |
? |
1.14.14.B9 | (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate + [reduced NADPH-hemoprotein reductase] + O2 |
- |
Homo sapiens |
(4Z,7Z,10Z,16Z,19Z)-13,14-epoxydocosa-4,7,10,16,19-pentaenoate + [oxidized NADPH-hemoprotein reductase] + H2O |
formation of 19,20-epoxydocosapentaenoic acid, 16,17-epoxydocosahexaenoic acid, 13,14-epoxydocosahexaenoic acid, and 10,11-epoxydocosahexaenoic acid, no significant formation of 21-hydroxy- or 22-hydroxydocosahexaenoic acid. Reaction is catalyzed by both isoforms CYP4F8 and CYP4F12 |
? |
1.14.14.B9 | (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate + [reduced NADPH-hemoprotein reductase] + O2 |
- |
Homo sapiens |
(4Z,7Z,13Z,16Z,19Z)-10,11-epoxydocosa-4,7,13,16,19-pentaenoate + [oxidized NADPH-hemoprotein reductase] + H2O |
formation of 19,20-epoxydocosapentaenoic acid, 16,17-epoxydocosahexaenoic acid, 13,14-epoxydocosahexaenoic acid, and 10,11-epoxydocosahexaenoic acid, no significant formation of 21-hydroxy- or 22-hydroxydocosahexaenoic acid. Reaction is catalyzed by both isoforms CYP4F8 and CYP4F12 |
? |
1.14.14.B9 | (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate + [reduced NADPH-hemoprotein reductase] + O2 |
- |
Homo sapiens |
(7Z,10Z,13Z,16Z)-19,20-epoxydocosa-7,10,13,16-tetraenoate + [oxidized NADPH-hemoprotein reductase] + H2O |
formation of 19,20-epoxydocosatetraenoic acid, 16,17-epoxydocosatetraenoic acid, 13,14-epoxydocosatetraenoic acid, and 10,11-epoxydocosatetraenoic acid, no formation of 21-hydroxy- or 22-hydroxydocosapentaenoic acid |
? |
1.14.14.B9 | (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate + [reduced NADPH-hemoprotein reductase] + O2 |
- |
Homo sapiens |
(7Z,10Z,13Z,19Z)-16,17-epoxydocosa-7,10,13,19-tetraenoate + [oxidized NADPH-hemoprotein reductase] + H2O |
formation of 19,20-epoxydocosapentaenoic acid, 16,17-epoxydocosapentaenoic acid, 13,14-epoxydocosapentaenoic acid, and 10,11-epoxydocosapentaenoic acid, no formation of 21-hydroxy- or 22-hydroxydocosapentaenoic acid |
? |
1.14.14.B9 | (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate + [reduced NADPH-hemoprotein reductase] + O2 |
- |
Homo sapiens |
(7Z,13Z,16Z,19Z)-10,11-epoxydocosa-7,13,16,19-tetraenoate + [oxidized NADPH-hemoprotein reductase] + H2O |
formation of 19,20-epoxydocosapentaenoic acid, 16,17-epoxydocosapentaenoic acid, 13,14-epoxydocosapentaenoic acid, and 10,11-epoxydocosapentaenoic acid, no formation of 21-hydroxy- or 22-hydroxydocosapentaenoic acid |
? |
1.14.14.B9 | arachidonic acid + [reduced NADPH-hemoprotein reductase] + O2 |
- |
Homo sapiens |
18-hydroxyarachidonic acid + [oxidized NADPH-hemoprotein reductase] + H2O |
hydroxylation at C-18 |
? |
1.14.14.B9 | astemizole + [reduced NADPH-hemoprotein reductase] + O2 |
- |
Macaca fascicularis |
? + [oxidized NADPH-hemoprotein reductase] + H2O |
- |
? |